Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 1998

View Archived Issues

Sankyo describes NK1/NK2 antagonists for treating asthma

Japanese lab describes new agents for asthma and inflammation

Deferiprone increases incidence of hepatic fibrosis and fails to control iron in thalassemia major

Eptifibatide treatment reduces incidence of death in acute myocardial infarction and unstable angina

Efficacy of collagen membrane delivery systems for rhBMP-2 in treatment of periodontal defects

Laboratory testing of new, more efficient Toleragen drug completed

First diagnostic kit for the detection of stroke developed by Skye PharmaTech

Elan and Endorex form new company to develop oral vaccines

Viagra and nitrates: a lethal combination

Anergen claims production methods for AnergiX compounds

Pfizer selects LTB4 antagonist for clinical testing

New agents for pancreatitis in early development at Sankyo

More asiatic acid derivatives in development at Dong Kook

Bristol-Myers Squibb discovers novel maxi-K channel openers

Toray reports kappa agonists for treating dermatological disorders

HERS study results now in -- results counter expectations

Disappointing results obtained in phase II/III trial of LU-25-109T

Onconase inhibits cancer cell growth and contributes to apoptosis

Il Yang synthesizes gastric H+/K+-ATPase inhibitors with improved stability

First approval for lamivudine in chronic hepatitis B

Nymox progresses with development of NX-B4221

FDA advisory committee meeting scheduled to review Enbrel BLA

Antiasthma drug candidate enters phase I testing at Pharmacia & Upjohn

Lilly describes promising beta3-adrenoceptor agonist at ACS meeting

ACS news flash: R.W. Johnson investigates thrombin inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...